Issue Date: April 27, 2009
Pfizer Strikes Deal With Malaria Venture
Pfizer and Medicines for Malaria Venture have signed an agreement that gives MMV access to Pfizer's library of novel chemical entities. Under the deal, scientists in institutes affiliated with MMV will test about 200,000 Pfizer compounds against Plasmodium falciparum, the parasite that causes malaria. The screening will take place at the Eskitis Institute for Cell & Molecular Therapies at Griffith University, in Australia.
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society